Want to see IN:THYROCARE full AI Analyst Report?

Thyrocare Technologies Ltd (THYROCARE) Price & Analysis

2 Followers

THYROCARE Stock Chart & Stats

₹459.10

-₹16.20(-1.70%)

At close: Jan 08 4:00 PM EST

₹459.10

-₹16.20(-1.70%)

Day’s Range― - ―

52-Week Range₹334.45 - ₹578.05

Previous CloseN/A

Volume114.81K

Average Volume (3M)56.30K

Market Cap

₹88.32B

Enterprise Value₹28.13B

Total Cash (Recent Filing)₹1.92B

Total Debt (Recent Filing)₹246.80M

Price to Earnings (P/E)26.3

Beta0.65

Next Earnings

Aug 04, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.68%

Share Statistics

EPS (TTM)24.16

Shares Outstanding159,165,310

10 Day Avg. Volume44,587

30 Day Avg. Volume56,302

Financial Highlights & Ratios

PEG Ratio-0.84

Price to Book (P/B)9.48

Price to Sales (P/S)6.69

P/FCF Ratio28.40

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)11.9

Revenue Forecast (FY)₹9.68B

Bulls Say, Bears Say

Bulls Say

Conservative Balance SheetVery low leverage (debt/equity ~0.09) and a strong equity base provide durable financial flexibility. This reduces refinancing and solvency risk, supports steady capital allocation for labs/network, and lets management pursue growth or returns without stressing cash flow during downturns.

Strong Cash GenerationHigh operating cash flow and FCF near reported earnings (FCF/net income ~0.9) point to earnings quality and repeatable cash conversion. Reliable cash allows reinvestment in automation, network expansion, or shareholder returns and cushions against cyclical volume swings.

Re-accelerating Revenue And MarginsRevenue re-acceleration and higher net margins demonstrate operational leverage from centralized, automated labs and a wide collection network. Sustained growth plus margin improvement enhances free cash flow potential and supports reinvestment into testing menu and capacity.

Bears Say

Margin VolatilitySharp year-to-year gross and net margin swings indicate sensitivity to pricing, test mix, or input costs. Persistent volatility undermines forecasting accuracy, can constrain long-term investment decisions, and raises the risk that current margins reverse under competitive or cost pressure.

Uneven Free Cash Flow GrowthWhile cash conversion is generally strong, inconsistent FCF growth reduces predictability of internal funding for expansion or M&A. Episodic declines force reliance on retained earnings or debt and complicate steady shareholder distributions or capex planning.

Rising But Modestly Increased Debt UsageAn uptick in debt usage, even from a low base, reduces the margin for error if margins re-contract. If management continues to add leverage to fund growth or working capital, interest costs and covenant risk could rise, limiting flexibility during weaker volume periods.

Thyrocare Technologies Ltd News

Thyrocare Sets Record Date for ₹7 Final Dividend for FY 2025-26

Thyrocare Technologies Ltd ( ($IN:THYROCARE) ) has issued an announcement. Thyrocare Technologies has announced that its board has...

1M ago

Thyrocare Files Business Responsibility and Sustainability Report for FY 2025-26

Thyrocare Technologies Ltd ( ($IN:THYROCARE) ) has shared an announcement. Thyrocare Technologies Limited has submitted its Business Responsibility...

1M ago

Thyrocare Shares AGM, Annual Report Links and Key Dividend Dates With Investors

Thyrocare Technologies Ltd ( ($IN:THYROCARE) ) has issued an announcement. Thyrocare Technologies Limited has notified stock exchanges that...

1M ago

Thyrocare Publishes Audited FY26 Results in Line with SEBI Norms

Thyrocare Technologies Ltd ( ($IN:THYROCARE) ) has shared an announcement. Thyrocare Technologies Ltd has published its audited financial...

2M ago

Thyrocare Receives ₹2.03 Crore Tax Demand, Plans to Contest

The latest update is out from Thyrocare Technologies Ltd ( ($IN:THYROCARE) ). Thyrocare Technologies has disclosed that it...

3M ago

Thyrocare boosts Tanzania subsidiary with fresh capital infusion

Thyrocare Technologies Ltd ( ($IN:THYROCARE) ) has shared an announcement. Thyrocare Technologies Ltd has infused an additional USD...

4M ago

Thyrocare Wins Dual Honours at National Diagnostics Forum 2026

Thyrocare Technologies Ltd ( ($IN:THYROCARE) ) has provided an announcement. Thyrocare Technologies Limited announced that it has received...

5M ago

Thyrocare Schedules January 28 Earnings Call to Discuss Q3 FY26 Results

The latest update is out from Thyrocare Technologies Ltd ( ($IN:THYROCARE) ). Thyrocare Technologies Limited has scheduled an...

6M ago

Thyrocare Auditor Converts to LLP Without Change in Audit Mandate

Thyrocare Technologies Ltd ( ($IN:THYROCARE) ) just unveiled an update. Thyrocare Technologies has announced that its statutory auditor,...

6M ago

Thyrocare Appoints Industry Veteran Rajdeep Panwar as Chief Commercial Officer

Thyrocare Technologies Ltd ( ($IN:THYROCARE) ) has issued an update. Thyrocare Technologies Limited has appointed senior healthcare and...

6M ago

THYROCARE FAQ

What was Thyrocare Technologies Ltd’s price range in the past 12 months?

Thyrocare Technologies Ltd lowest stock price was ₹334.45 and its highest was ₹578.05 in the past 12 months.

What is Thyrocare Technologies Ltd’s market cap?

Thyrocare Technologies Ltd’s market cap is ₹88.32B.

When is Thyrocare Technologies Ltd’s upcoming earnings report date?

Thyrocare Technologies Ltd’s upcoming earnings report date is Aug 04, 2026 which is in 31 days.

How were Thyrocare Technologies Ltd’s earnings last quarter?

Thyrocare Technologies Ltd released its earnings results on May 07, 2026. The company reported ₹3.03 earnings per share for the quarter, missing the consensus estimate of ₹5.4 by -₹2.37.

Is Thyrocare Technologies Ltd overvalued?

According to Wall Street analysts Thyrocare Technologies Ltd’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Thyrocare Technologies Ltd pay dividends?

Thyrocare Technologies Ltd pays a Quarterly dividend of ₹7 which represents an annual dividend yield of 0.68%. See more information on Thyrocare Technologies Ltd dividends here

What is Thyrocare Technologies Ltd’s EPS estimate?

Thyrocare Technologies Ltd’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Thyrocare Technologies Ltd have?

Thyrocare Technologies Ltd has 159,165,310 shares outstanding.

What happened to Thyrocare Technologies Ltd’s price movement after its last earnings report?

Thyrocare Technologies Ltd reported an EPS of ₹3.03 in its last earnings report, missing expectations of ₹5.4. Following the earnings report the stock price went up 1.737%.

Which hedge fund is a major shareholder of Thyrocare Technologies Ltd?

Currently, no hedge funds are holding shares in IN:THYROCARE

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Thyrocare Technologies Ltd

Thyrocare Technologies Limited, an Indian enterprise, delivers a comprehensive array of diagnostic testing solutions to individual patients, medical laboratories, and healthcare providers throughout the nation. Its operations are structured across three main segments: Diagnostic Testing Services, Imaging Services, and other miscellaneous endeavors. The company's primary focus involves conducting numerous medical diagnostic analyses and specialized test panels aimed at the timely detection and effective management of various health conditions. These include, among others, disorders related to the thyroid, growth, metabolism, autoimmune responses, diabetes, anemia, cardiovascular health, infertility, COVID-19, and a broad spectrum of infectious diseases. Under its "Aarogyam" brand, Thyrocare offers 34 distinct profiles of tests, providing patients with extensive wellness and preventative health check-ups. Furthermore, the company sells "Sugarscan" branded glucometers and glucostrips, along with various consumable products and radiopharmaceuticals. Founded in 1996, Thyrocare Technologies Limited is headquartered in Navi Mumbai, India, and functions as a subsidiary of Docon Technologies Private Limited.